|Day Low/High||252.50 / 256.15|
|52 Wk Low/High||184.50 / 261.27|
Jim Cramer is bullish on Hertz Global Holdings, Honeywell, PetMed Express, and Allergan.
Here are the activist investor's next potential targets.
Jim Cramer says these market rotations are crushing good stocks that don't deserve it.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Allergan PLC has taken over the #90 spot from Danaher Corp , according to ETF Channel. Below is a chart of Allergan PLC versus Danaher Corp plotting their respective rank within the S&P 500 over time (AGN plotted in blue; DHR plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.
The market surged this week as positive earnings and a mellower tone from Janet Yellen cheered bulls.
Jim Cramer warns that development stage biotechs are for speculation only.
Cramer says it's the sign of a good market: Investors are finding value in the stocks that were left behind.
First Amgen and Allergan Oncology Biosimilar Candidate to be Reviewed by U.S. FDA Advisory Committee
We are actively looking at CSCO to make a move.
The Trump administration's creep towards scrapping certain tax regulations could revive inversion deals that have allowed U.S. companies to avoid billions of dollars in taxes.
The Treasury Department is targeting a handful of Obama-era tax rules for reform, including one that could resurrect corporate inversions.
Allergan partners with Milo Ventimiglia, Victor Cruz, and Alexandra Daddario to promote vision health and raise money for the American Foundation for the Blind
Jobs report and Fed minutes highlight a short week. In the portfolio, we add one name and downgrade another.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allergan, Inc.
Lilly sued Actavis, saying its generic product would still infringe on Lilly's vitamin regimens regardless of any dilution.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of investors that sold the call options, purchased the put options and/or sold equity forward contracts of...
We held back on any big portfolio moves as the quarter ended with bank stress test results and merger news.